Results from a pivotal Phase 3 study evaluating Voclosporin (also known as ISA247) for plaque psoriasis were published on 2008-01-01. This randomized, multicentre, double-blind, placebo-controlled trial investigated the efficacy of the drug in patients with this chronic inflammatory skin condition.
Background
Voclosporin (ISA247) is a drug that was investigated for its potential in treating plaque psoriasis, a common, chronic, non-contagious autoimmune disease characterized by raised, red, scaly patches on the skin. The publication of a Phase 3 study indicates a significant stage in its clinical development for this indication.
Trial design
The published study was a Phase 3, randomized, multicentre, double-blind, placebo-controlled trial. It specifically evaluated Voclosporin (ISA247) for the treatment of plaque psoriasis. The design aimed to rigorously assess the drug's efficacy compared to a placebo, ensuring a high standard of evidence for its potential benefits in this patient population.
What this means
The publication of results from a pivotal Phase 3 study represents a crucial milestone in the development of Voclosporin (ISA247) for plaque psoriasis. While specific quantitative efficacy data is not detailed in this summary, the completion and publication of a randomized, multicentre, double-blind, placebo-controlled trial indicate that a comprehensive evaluation of the drug's potential benefits in this patient population has been conducted. Clinicians and researchers would refer to the full publication for detailed findings on the drug's efficacy and safety profile.
Source
The information for this update was sourced from PubMed, detailing the publication of a pivotal Phase 3 study on 2008-01-01. The article, titled "Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study," is available on pubmed.ncbi.nlm.nih.gov.